Close Menu

NEW YORK – The US Food and Drug Administration has updated its requirements for molecular diagnostic developers seeking Emergency Use Authorization for COVID-19 tests to include the use of actual positive specimens.

In the eighth of its weekly virtual town hall meetings on Wednesday, Timothy Stenzel, director of the agency's office if in vitro diagnostics and radiological health, said going forward FDA will require developers to use such specimens as part of the validation process.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.